JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Millan, M. J.
Right arrow Articles by Lavielle, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Millan, M. J.
Right arrow Articles by Lavielle, G.

Vol. 293, Issue 3, 1048-1062, June 2000

S33084, a Novel, Potent, Selective, and Competitive Antagonist at Dopamine D3-Receptors: I. Receptorial, Electrophysiological and Neurochemical Profile Compared with GR218,231 and L741,626

Mark J. Millan, Alain Gobert, Adrian Newman-Tancredi, Françoise Lejeune, Didier Cussac, Jean-Michel Rivet, Valérie Audinot, Thierry Dubuffet and Gilbert Lavielle

Departments of Psychopharmacology (M.J.M., A.G., A.N.-T., F.L., D.C., J.-M.R., V.A.) and Chemistry F (T.D., G.L.), Institut de Recherches Servier, Centre de Recherches de Croissy, Paris, France

The benzopyranopyrrole S33084 displayed pronounced affinity (pKi = 9.6) for cloned human hD3-receptors, and >100-fold lower affinity for hD2 and all other receptors (>30) examined. S33084 concentration dependently, potently, and competitively (pA2 = 9.7) antagonized dopamine (DA)-induced [35S]guanosine-5'- O-(3-thio)triphosphate (GTPgamma S) binding at hD3-receptors. It also concentration dependently abolished stimulation by DA of hD3-receptor-coupled mitogen-activated protein kinase. Administered alone, S33084 did not modify dialysate levels of DA in the frontal cortex, nucleus accumbens, or striatum of freely moving rats, nor the firing rate of ventrotegmental dopaminergic cell bodies. Furthermore, it had minimal effect on DA turnover in mesocortical, mesolimbic, and nigrostriatal projection regions. However, S33084 dose dependently blocked the suppressive influence of the preferential D3-agonist PD128,907 on frontocortical release of DA. Furthermore, it likewise antagonized the inhibitory influence of PD128,907 on the electrical activity of ventrotegmental dopaminergic neurons. Although less potent than S33084, GR218,231 likewise behaved as a selective hD3- versus hD2-receptor antagonist and its neurochemical and electrophysiological profiles were similar. In contrast, L741,626 was a preferential antagonist at hD2 versus hD3 sites. In vivo, on administration alone, L741,626 increased frontocortical, mesolimbic, and (more potently) striatal DA release, enhanced the firing rate of dopaminergic perikarya, and accelerated cerebral DA synthesis. It also blocked the actions of PD128,907. In conclusion, S33084 is a novel, potent, selective, and competitive antagonist at hD3-receptors. Although GR218,231 behaves similarly, L741,626 is a preferential D2-receptor antagonist. DA D2- but not D3-(auto) receptors tonically inhibit ascending dopaminergic pathways, although the latter may contribute to phasic suppression of DA release in frontal cortex.

0022-3565/00/2933-1048$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2000 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
G. T. Collins, D. M. Calinski, A. H. Newman, P. Grundt, and J. H. Woods
Food Restriction Alters N'-Propyl-4,5,6,7-tetrahydrobenzothiazole-2,6-diamine dihydrochloride (Pramipexole)-Induced Yawning, Hypothermia, and Locomotor Activity in Rats: Evidence for Sensitization of Dopamine D2 Receptor-Mediated Effects
J. Pharmacol. Exp. Ther., May 1, 2008; 325(2): 691 - 697.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
M. J. Millan, C. M. la Cour, F. Novi, R. Maggio, V. Audinot, A. Newman-Tancredi, D. Cussac, V. Pasteau, J.-A. Boutin, T. Dubuffet, et al.
S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], A Preferential Dopamine D3 versus D2 Receptor Antagonist and Potential Antipsychotic Agent: I. Receptor-Binding Profile and Functional Actions at G-Protein-Coupled Receptors
J. Pharmacol. Exp. Ther., February 1, 2008; 324(2): 587 - 599.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
M. J. Millan, P. Svenningsson, C. R. Ashby Jr., M. Hill, M. Egeland, A. Dekeyne, M. Brocco, B. Di Cara, F. Lejeune, N. Thomasson, et al.
S33138 [N-[4-[2-[(3aS,9bR)-8-Cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a Preferential Dopamine D3 versus D2 Receptor Antagonist and Potential Antipsychotic Agent. II. A Neurochemical, Electrophysiological and Behavioral Characterization in Vivo
J. Pharmacol. Exp. Ther., February 1, 2008; 324(2): 600 - 611.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
E. F.J. de Vries, R. Kortekaas, A. van Waarde, D. Dijkstra, P. H. Elsinga, and W. Vaalburg
Synthesis and Evaluation of Dopamine D3 Receptor Antagonist 11C-GR218231 as PET Tracer for P-Glycoprotein
J. Nucl. Med., August 1, 2005; 46(8): 1384 - 1392.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
M. J. Millan, D. Cussac, A. Gobert, F. Lejeune, J.-M. Rivet, C. M. La Cour, A. Newman-Tancredi, and J.-L. Peglion
S32504, a Novel Naphtoxazine Agonist at Dopamine D3/D2 Receptors: I. Cellular, Electrophysiological, and Neurochemical Profile in Comparison with Ropinirole
J. Pharmacol. Exp. Ther., June 1, 2004; 309(3): 903 - 920.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
M. Lapinsh, P. Prusis, T. Lundstedt, and J. E. S. Wikberg
Proteochemometrics Modeling of the Interaction of Amine G-Protein Coupled Receptors with a Diverse Set of Ligands
Mol. Pharmacol., June 1, 2002; 61(6): 1465 - 1475.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
M. J. Millan, A. Dekeyne, J.-M. Rivet, T. Dubuffet, G. Lavielle, and M. Brocco
S33084, a Novel, Potent, Selective, and Competitive Antagonist at Dopamine D3-Receptors: II. Functional and Behavioral Profile Compared with GR218,231 and L741,626
J. Pharmacol. Exp. Ther., June 1, 2000; 293(3): 1063 - 1073.
[Abstract] [Full Text]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2000 by the American Society for Pharmacology and Experimental Therapeutics.